Hydroquinone-Induced Depigmentation: Case Report and Review of the Literature

Abstract

Melasma is an acquired cutaneous disorder caused by an overproduction of melanin by the enzyme tyrosinase. Melasma remains a therapeutic challenge and no definitive standard therapy exists. Although hydroquinone (HQ) has emerged as the most common treatment, its popularity has recently waned because of concerns about its potential carcinogenicity and manufacturing challenges. The adverse effects of HQ range from the common irritant contact dermatitis to the less frequent exogenous ochronosis (EO). Previous reports suggest that the risk of leukoderma from HQ treatment is limited to individuals of African descent. Herein, we describe for the first time the development of depigmentation and paradoxical hyperpigmentation in 2 patients with Fitzpatrick skin type III/IV after brief treatment of their melasma with the HQ-containing Nu-Derm and Reverse systems.

Get full access to this article

View all access options for this article.

References

Bandyopadhyay

. Topical treatment of melasma. Indian J Dermatol, 2009; 54 (4): –.

Gupta

, Gover

, Nouri

, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol, 2006; 55 (6): 1048–1065.

Kang

, Ortonne

. What should be considered in treatment of melasma. Ann Dermatol, 2010; 22 (4): 373–378.

Abu Ubeid

, Zhao

, Wang

, et al. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol, 2009; 129 (9): 2242–2249.

Grimes

, Yamada

, Bhawan

. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol, 2005; 27 (2): 96–101.

Halder

, Richards

. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett, 2004; 9 (6): 1–3.

. Hydroquinone for skin lightening: safety profile, duration of use and when should we stop?. J Dermatolog Treat, 2010; 21 (5): 272–275.

Oettel

Die hydrochinonvergiftung. Arch Exp Pathol Pharmacol, 1936; 183: 319–362.

Westerhof

, Kooyers

. Hydroquinone and its analogues in dermatology—a potential health risk. J Cosmet Dermatol, 2005; 4 (2): 55–59.

10.

Davis

, Callender

. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol, 2010; 3 (7): 20–31.

11.

Markey

, Black

, Rycroft

. Confetti-like depigmentation from hydroquinone. Contact Dermatitis, 1989; 20 (2): 148–149.

12.

Kersey

, Stevenson

. Vitiligo and occupational exposure to hydroquinone from servicing self-photographing machines. Contact Dermatitis, 1981; 7 (5): 285–287.

13.

Fisher

. Leukoderma from bleaching creams containing 2% hydroquinone. Contact Dermatitis, 1982; 8 (4): 272–273.

14.

Anonymous. Can bleaching creams containing 2% hydroquinone produce leukoderma?. J Am Acad Dermatol, 1982; 7 (1): 134–135.

15.

Chivers

. Two cases of occupational leucoderma following contact with hydroquinone monomethyl ether. Br J Ind Med, 1972; 29 (1): 105–107.

16.

Ladizinski

, Mistry

, Kundu

. Widespread use of toxic skin lightening compounds: medical and psychosocial aspects. Dermatol Clin, 2011; 29 (1): 111–123.

17.

Anderson

. Corneal and conjunctival pigmentation among workers engaged in manufacture of hydroquinone. Arch Ophthal, 1947; 38 (6): 812–826.

18.

Nordlund

, Grimes

, Ortonne

. The safety of hydroquinone. J Eur Acad Dermatol Venereol, 2006; 20 (7): 781–787.

19.

Levitt

. The safety of hydroquinone: a dermatologist’s response to the 2006 Federal Register. J Am Acad Dermatol, 2007; 57 (5): 854–872.

20.

Frenk

, Loi-Zedda

. Occupational depigmentation due to a hydroquinone-containing photographic developer. Contact Dermatitis, 1980; 6 (3): 238–239.

21.

Whittington

. Hypopigmentation from UV resin additive. Contact Dermatitis, 1981; 7 (6): 289–292.

22.

Findlay

, Morrison

, Simson

. Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. British Journal of Dermatology, 1975; 93: 613–622.